Evidence map›Paper›PMID 24881813›Full record

ArticleGene2014

Epigenetic landscape during osteoblastogenesis defines a differentiation-dependent Runx2 promoter region.

Phillip W L Tai, Hai Wu, Jonathan A R Gordon, Troy W Whitfield, A Rasim Barutcu, André J van Wijnen, Jane B Lian, Gary S Stein, Janet L Stein

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Downregulation of Nesprin1 by Runx2 deficiency is critical for the development of skeletal laminopathy-like pathology.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Epigenetic Control of Osteogenic Lineage Commitment.Frontiers in cell and developmental biology · 2020
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Phillip W L TaiDepartment of Biochemistry, University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405-0068, USA. Electronic address: phillip.tai@med.uvm.edu.
Hai WuDepartment of Biochemistry, University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405-0068, USA. Electronic address: hai.wu@uvm.edu.
Jonathan A R GordonDepartment of Biochemistry, University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405-0068, USA. Electronic address: jonathan.a.gordon@uvm.edu.
Troy W WhitfieldDepartment of Cell and Developmental Biology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655-0002, USA. Electronic address: troy.whitfield@umassmed.edu.
A Rasim BarutcuDepartment of Cell and Developmental Biology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655-0002, USA. Electronic address: rasim.barutcu@umassmed.edu.
André J van WijnenMayo Clinic, 200 First Street SW, Rochester, MN 55905-0001, USA. Electronic address: vanwijnen.andre@mayo.edu.
Jane B LianDepartment of Biochemistry, University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405-0068, USA. Electronic address: Jane.Lian@med.uvm.edu.
Gary S SteinDepartment of Biochemistry, University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405-0068, USA. Electronic address: Gary.Stein@med.uvm.edu.
Janet L SteinDepartment of Biochemistry, University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405-0068, USA. Electronic address: Janet.Stein@med.uvm.edu.
University of Vermont · USUniversity of Massachusetts Chan Medical School · USMayo Clinic · US

Funding

SUBNUCLEAR TARGETING OF TRANSCRIPTION FACTORSP01CA082834 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STEIN, GARY S. · 2001 to 2015
$18.4M
Subnuclear Integration of Regulatory Signals Controlling Bone Cell FunctionP01AR048818 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI STEIN, JANET L · 2002 to 2011
$14.0M
CONTROL OF OSTEOBLAST PROLIFERATION AND DIFFERENTIATIONR01AR039588 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LIAN, JANE B., STEIN, GARY S. · 1990 to 2019
$8.0M
Synthesis of Osteocalcin in BoneR37DE012528 · NIDCR · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LIAN, JANE B. · 2008 to 2017
$5.0M
NCI NIH HHS P01 CA082834NIAMS NIH HHS P01 AR048818NIAMS NIH HHS P01 AR48818NIAMS NIH HHS R01 AR039588NIDCR NIH HHS R37 DE012528
6 · The paper itself

Abstract

Runx2 is a developmentally regulated gene in vertebrates and is essential for bone formation and skeletal homeostasis. The induction of runx2-P1 isoform transcripts is a hallmark of early osteoblastogenesis. Although previous in vitro studies have defined a minimal Runx2-P1 promoter sequence with well-characterized functional elements, several lines of evidence suggest that transcription of the Runx2-P1 isoform relies on elements that extend beyond the previously defined P1 promoter boundaries. In this study, we examined Runx2-P1 transcriptional regulation in a cellular in vivo context during early osteoblastogenesis of MC3T3-E1 cultures and BMSCs induced towards the bone lineage by multi-layered analysis of the Runx2-P1 gene promoter using the following methodologies: 1) sequence homology among several mammalian species, 2) DNaseI hypersensitivity coupled with massively parallel sequencing (DNase-seq), and 3) chromatin immunoprecipitation of activating histone modifications coupled with massively parallel sequencing (ChIP-seq). These epigenetic features have allowed the demarcation of boundaries that redefine the minimal Runx2-P1 promoter to include a 336-bp sequence that mediates responsiveness to osteoblast differentiation. We also find that an additional level of control is contributed by a regulatory region in the 5'-UTR of Runx2-P1.

Indexed as

Epigenesis, GeneticAnimalsBase SequenceCell DifferentiationCell LineCells, CulturedCore Binding Factor Alpha 1 SubunitLuciferasesMice, Inbred C57BLMice, TransgenicMolecular Sequence DataOsteoblastsOsteogenesisPromoter Regions, GeneticProtein IsoformsReverse Transcriptase Polymerase Chain ReactionCore Binding Factor Alpha 1 SubunitLuciferasesProtein IsoformsRunx2 protein, mouseDNase hypersensitivityGene regulationHistone modificationOsteoblast differentiationRunx2-P1

Identifiers

PMID24881813
PMCPMC4149845
OpenAlexW2010358722

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.